The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep.

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

ResMed, the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, has launched AirSense 11 in India. The company’s next-generation Continuous Positive ...

The Sleep and Breathing Health segment ... its integrated care capabilities. ResMed is known to leverage trends such as artificial intelligence (AI) and machine learning to bolster its product ...